Dynavax Announces Webcast of R&D Day
(firmenpresse) - BERKELEY, CA -- (Marketwired) -- 12/09/14 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company will host a live webcast in conjunction with its Research and Development (R&D) Day on Thursday, December 11, 2014 in New York City. This event for institutional investors will focus on Dynavax's leadership in the application of toll-like receptor (TLR) biology, including updates on its Phase 3 investigational adult hepatitis B vaccine, HEPLISAV-B™, clinical programs in cancer and asthma, and advancing preclinical candidates. The webcast of the presentations and Q&A will begin at 8:30 a.m. ET and is scheduled to conclude at 11:00 a.m. ET.
The R&D Day will include presentations by Dynavax senior leadership, including Eddie Gray, Chief Executive Officer; Robert Coffman, Chief Scientific Officer; and Robert Janssen, Chief Medical Officer. They will discuss Dynavax's business and areas of R&D focus and provide a scientific overview of TLR immune modulation and its application to the Company's programs. Detailed updates will also be provided on the status of HEPLISAV-B, Dynavax's investigational adult hepatitis B vaccine and most advanced TLR-based product, and SD-101, its lead clinical-stage candidate in cancer immunotherapy.
Two nationally recognized clinical experts in the field of cancer immunotherapy will join the company presenters:
Ronald Levy, M.D., Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine and
Antoni Ribas, M.D., Professor of Medicine, David Geffen UCLA School of Medicine and Director, JCCC Tumor Immunology Program
Dr. Levy will discuss the rationale for intratumoral injection of SD-101 and ongoing and planned studies in lymphoma with SD-101, combined with local radiation or an anti-CTLA4 antibody. Dr. Ribas will address the challenges and opportunities of immunotherapy combinations in other tumor types, including the rationale for using intratumoral SD-101 as a synergistic combination with an anti-PD-1 antibody in patients with metastatic melanoma.
A link to the live webcast may be accessed by visiting the "Investors" section of the Dynavax website or reached directly at: .
Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit .
Contact:
Michael Ostrach
Chief Business and Principal Financial Officer
510-665-7257
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.12.2014 - 11:00 Uhr
Sprache: Deutsch
News-ID 358039
Anzahl Zeichen: 0
contact information:
Town:
BERKELEY, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 220 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dynavax Announces Webcast of R&D Day"
steht unter der journalistisch-redaktionellen Verantwortung von
Dynavax Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
